MASTERPLAN
Start here
The MASTERPLAN trial, an open-label phase 2 multicentre randomised study run by the Australasian Gastro-Intestinal Trials Group, tested whether adding stereotactic body radiotherapy to perioperative chemotherapy improves outcomes for patients with high-risk, localised pancreatic ductal adenocarcinoma. Results, published in The Lancet Oncology, show that the combined approach significantly reduced locoregional recurrence compared with perioperative chemotherapy alone, and did so without a significant increase in toxicity. The authors regard the strategy as worth pursuing in larger studies. The trial was phase 2, so the magnitude of benefit and the role of SBRT in standard perioperative care remain open questions awaiting confirmation in bigger datasets.
Written by a model from the reports · updated 4 hours ago
Developments
- Oct 24 00:00 · 1 reportMASTERPLAN试验评估化疗联合立体定向放疗thelancet.com · [Articles] Perioperative chemotherapy and stereotactic body radiotherapy versus perioperative chemotherapy alone in patients with high-risk, localised pancreatic cancer (MASTERPLAN): an open-label, phase 2, multicentre, randomised trial of the Australasian Gastro-Intestinal Trials Group
- Oct 23 05:55 · 2 reports🔥AGITG MASTERPLAN🔥 Borderline resectable or Locally advanced PDAC n=75 🔍Randomized 3m mFOLFIRINOX or Gem+nab-Paclitaxel alone +/- SBRT (4x.com · 🔥AGITG MASTERPLAN🔥 Borderline resectable or Locally advanced PDAC n=75 🔍Randomized 3m mFOLFIRINOX or Gem+nab-Paclitaxel alone +/- SBRT (40 Gy/5 fx) Primary endpoint: locoregiona…
Coverage timeline
Follow the coverage to see the different angles.
- thelancet.com[Articles] Perioperative chemotherapy and stereotactic body radiotherapy versus perioperative chemotherapy alone in patients with high-risk, localised pancreatic cancer (MASTERPLAN): an open-label, phase 2, multicentre, randomised trial of the Australasian Gastro-Intestinal Trials Group
The open-label, phase 2, multicentre MASTERPLAN randomised trial by the Australasian Gastro-Intestinal Trials Group (AGITG) showed that perioperative chemotherapy plus SBRT significantly reduced locoregional recurrence in high-risk, localised PDAC. Compared with perioperative chemotherapy alone, adding SBRT did not significantly increase toxicity; the authors say the strategy warrants investigation in larger studies.
Heat trend for this story
Heat now 19·Peak in the comparable set 21 (Oct 24 01:00)·Change over 24h in the comparable set –·Participants now 3
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.